Enfusion Statistics
Share Statistics
Enfusion has 94.37M shares outstanding. The number of shares has increased by 5.01% in one year.
| Shares Outstanding | 94.37M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 1.25% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 49.29M |
| Failed to Deliver (FTD) Shares | 222 |
| FTD / Avg. Volume | 0.05% |
Short Selling Information
The latest short interest is 811.20K, so 0.86% of the outstanding shares have been sold short.
| Short Interest | 811.20K |
| Short % of Shares Out | 0.86% |
| Short % of Float | 1.65% |
| Short Ratio (days to cover) | 1.83 |
Valuation Ratios
The PE ratio is 142 and the forward PE ratio is 32.76. Enfusion 's PEG ratio is 0.44.
| PE Ratio | 142 |
| Forward PE | 32.76 |
| PS Ratio | 4.9 |
| Forward PS | 3.4 |
| PB Ratio | 15.94 |
| P/FCF Ratio | 53.6 |
| PEG Ratio | 0.44 |
Enterprise Valuation
Enfusion Inc. has an Enterprise Value (EV) of 835.39M.
| EV / Earnings | 138.65 |
| EV / Sales | 4.79 |
| EV / EBITDA | 38.08 |
| EV / EBIT | 69.92 |
| EV / FCF | 52.33 |
Financial Position
The company has a current ratio of 3.44, with a Debt / Equity ratio of 0.
| Current Ratio | 3.44 |
| Quick Ratio | 3.44 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is 0.11% and return on capital (ROIC) is 10.36%.
| Return on Equity (ROE) | 0.11% |
| Return on Assets (ROA) | 0.06% |
| Return on Capital (ROIC) | 10.36% |
| Revenue Per Employee | 158.38K |
| Profits Per Employee | 5.47K |
| Employee Count | 1.10K |
| Asset Turnover | 1.6 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 2.23M |
| Effective Tax Rate | 0.19 |
Stock Price Statistics
The stock price has increased by 10.03% in the last 52 weeks. The beta is 0.93, so Enfusion 's price volatility has been higher than the market average.
| Beta | 0.93 |
| 52-Week Price Change | 10.03% |
| 50-Day Moving Average | 9.91 |
| 200-Day Moving Average | 9.16 |
| Relative Strength Index (RSI) | 46.76 |
| Average Volume (20 Days) | 433.77K |
Income Statement
In the last 12 months, Enfusion had revenue of 174.53M and earned 6.03M in profits. Earnings per share was 0.1.
| Revenue | 174.53M |
| Gross Profit | 116.89M |
| Operating Income | 11.95M |
| Net Income | 6.03M |
| EBITDA | 21.93M |
| EBIT | 11.95M |
| Earnings Per Share (EPS) | 0.1 |
Balance Sheet
The company has 35.60M in cash and 15.44M in debt, giving a net cash position of 20.17M.
| Cash & Cash Equivalents | 35.60M |
| Total Debt | 15.44M |
| Net Cash | 20.17M |
| Retained Earnings | -172.93M |
| Total Assets | 134.94M |
| Working Capital | 61.87M |
Cash Flow
In the last 12 months, operating cash flow was 25.63M and capital expenditures -9.67M, giving a free cash flow of 15.96M.
| Operating Cash Flow | 25.63M |
| Capital Expenditures | -9.67M |
| Free Cash Flow | 15.96M |
| FCF Per Share | 0.18 |
Margins
Gross margin is 6.70K%, with operating and profit margins of 685% and 345%.
| Gross Margin | 6.70K% |
| Operating Margin | 685% |
| Pretax Margin | 658% |
| Profit Margin | 345% |
| EBITDA Margin | 12.57% |
| EBIT Margin | 6.85% |
| FCF Margin | 9.15% |
Dividends & Yields
ENFN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 0.99% |
| FCF Yield | 1.68% |
Analyst Forecast
The average price target for ENFN is $9, which is -10.8% lower than the current price. The consensus rating is "Sell".
| Price Target | $9 |
| Price Target Difference | -10.8% |
| Analyst Consensus | Sell |
| Analyst Count | 5 |
Scores
| Altman Z-Score | 15.86 |
| Piotroski F-Score | 6 |